

Name	Eri Matsuki
Current Position & Affiliation	Assistant Professor, Keio University School of Medicine, Division of Hematology, Department of Medicine Division Chair, Division of Network Support, Clinical and Translational Research Center, Keio University Hospital
Country	Japan
Major Field	Chronic myeloid leukemia, B-cell malignancies

Educational Background	
April, 1998 - March, 2004	MD, Keio University School of Medicine
April, 2007 - March, 2011	PhD in Medicine (Hematology), Keio University Graduate School of Medicine, Tokyo, Japan
July, 2013 - May, 2014	MPH, Harvard School of Public Health (Clinical Effectiveness Concentration)
July, 2021 - December, 2022	Post-master's Certificate Course in Health Information Management, University of Illinois in Chicago

Professional Experience	
April, 2004 - March, 2006	Intern at Keio University Hospital, Tokyo, Japan / Yokohama Municipal Citizen's Hospital, Kanagawa, Japan
April, 2006 - March, 2007	Resident in Internal Medicine, Pediatrics Yokohama Municipal Citizen's Hospital, Kanagawa, Japan
April, 2007 - March, 2008	Resident in Internal Medicine, Keio University School of Medicine, Tokyo, Japan
April, 2008 - March, 2012	Fellow in Hematology/Oncology, Keio University School of Medicine, Tokyo, Japan
April, 2012 - June, 2013	Instructor of Hematology, Keio University School of Medicine
July, 2014 - September, 2015	Visiting Investigator, Memorial Sloan-Kettering Cancer Center
October, 2015 - May, 2017	Chief of Hematology Service, Tachikawa Hospital
June, 2017 - March, 2021	Instructor of Hematology, Keio University School of Medicine
July, 2017 - April, 2018	Instructor, Keio University School of Medicine Clinical and Translational Research Center
May, 2018 - June, 2020	Deputy Manager for the Division of Clinical Research and Trials, Department of Clinical Research and Trials, Japan Agency for Medical Research and Development
July, 2020 - March, 2021	Instructor, Keio University School of Medicine, Clinical and Translational Research Center
April, 2021 - April, 2021	Assistant Professor, Keio University School of Medicine, Clinical and Translational Research Center
May, 2021 - current	Assistant Professor, Keio University School of Medicine, Division of Hematology, Department of Medicine

Other Experience and Professional Memberships	
2004	The Japanese Society of Internal Medicine
2006	Japanese Society of Medical Oncology
2006	The Japanese Society of Hematology
2007	The Japan Society for Hematopoietic Cell Transplantation

2007	The Japanese Association for Infectious Diseases
2010	The Japanese Society for Laboratory Hematology
2011	American Society of Hematology
2011	American Society of Clinical Oncology
2013	American Association for Cancer Research
2020	Japan Association for Medical Informatics
2022	American Medical Informatics Association
2022	Healthcare Information and Management Systems Society

Main Scientific Publications

- 1 [Matsuki E](#), Miyakawa Y, Okamoto S. A novel factor XII mutation, FXII R84P, causing factor XII deficiency in a patient with hereditary spastic paraplegia. *Blood Coagulation & Fibrinolysis*, 2011; 22(3): 227-30.
 - 2 [Matsuki E](#), Tsukada Y, Nakaya A, Yokoyama K, Okamoto S. Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy. *Internal Medicine*, 2011; 50(8): 909-14.
 - 3 [Matsuki E](#), Miyakawa Y., Asakawa S., et al. Identification of loss of p16 expression and upregulation of MDR-1 as genetic events resulting from two novel chromosomal translocations found in a plasmablastic lymphoma of the uterus. *Clinical Cancer Research*, 2011; 17(8): 2101-9
 - 4 [Matsuki E](#), Miyakawa Y, Yamane A, Okamoto S. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation. *Exp Hematol.*, 2011; 39(8): 829-36
 - 5 [Matsuki E](#), Matsumoto K, Nakaya A, Yamane A, Kato J, Okamoto S. Marked improvement of anemia during treatment with deferasirox in a patient with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes. *Rinsho Ketsueki*, 2012; 53(1): 78-82 (in Japanese)
 - 6 Matsushita M, Tonegawa K, Mori T, Kohashi S, Kato J, [Matsuki E](#), Okamoto S, Hattori Y. Detection of leukemia associated antigen-specific cytotoxic T cells in a patient with Philadelphia chromosome-positive leukemia during treatment with dasatinib. *Leuk Lymphoma*, 2014; 55: 722 – 724.
 - 7 Kumagai T, [Matsuki E](#), Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. *Int J Hematol*, 2014; 99: 41 – 52.
 - 8 Inokuchi K, Kumagai T, [Matsuki E](#), Ohashi K, Shinagawa A, Hata Y, Takeuchi J, Yoshida C, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Okamoto S, Oba K, Sakamoto J, Sakamaki H. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to response to dasatinib in imatinibi-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. *J Clin Exp Hematopathology*, 2014.
 - 9 [Matsuki E](#), Younes A. Lymphomagenesis in Hodgkin lymphoma. *Seminars in cancer biology*. 2015; 34:14-21.
 - 10 [Matsuki E](#), Younes A. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. *Curr Treat Options Oncol*. 2016 Jun;17(6):31.
 - 11 Batlevi CL, [Matsuki E](#), Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. *Nature reviews. Clinical oncology*. 2016; 13(1):25-40.
 - 12 [Matsuki E](#), Bohn OL, El Jamal S, Pichardo JD, Zelenetz AD, Younes A, Teruya-Feldstein J. Lymphocyte-to-monocyte ratio may serve as a better prognostic indicator than tumor-associated macrophages in DLBCL treated with rituximab. *Appl Immunohistochem Mol Morphol*. 2019; 27(8):572-580.
 - 13 Sakurai M, Kikuchi T, Karigane D, Kasahara H, [Matsuki E](#), Hashida R, Yamane Y, Abe R, Koda Y, Toyama T, Kato J, Shimizu T, Yokoyama Y, Suzuki S, Nakamura T, Okamoto S, Mori T. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. *Int J Hematol*, 2019; 109(3): 292-298.
 - 14 [Matsuki E](#), Kawamoto S, Morikawa Y, Yahagi N. The Impact of Cold Ambient Temperature in the Pattern of Influenza Virus Infection. *Open Forum Infect Dis*, 2023; 10(2):ofad039.
 - 15 Sakurai M, Kogure Y, Mizuno K, [Matsuki E](#), Kataoka K. Long-term reduction in the incidence of aplastic
-

-
- anemia and immune thrombocytopenia during the COVID-19 pandemic. *Haematologica*, 2023; 108(9): 2546-2550.
- 16 Kondo T, Matsuki E, Takaku T, Watanabe N, Yoshida C, Okada M, Murai K, Kodama T, Takahashi N, Kimura S, Matsumura I; Preg-CML/Japan Study Investigators. Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. *Cancer*. 2024. Epub ahead of print.
-

